Streetbeat News

Price Targets

ROST

Gordon Haskett analyst Chuck Grom downgraded Ross Stores (NASDAQ:ROST) from Buy to Accumulate and announced a $120 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:40 am

WKC

B of A Securities analyst Ken Hoexter downgrades World Kinect (NYSE:WKC) from Buy to Underperform and announces a $22 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:38 am

PLYA

B of A Securities analyst Shaun Kelley downgraded Playa Hotels & Resorts (NASDAQ:PLYA) from Buy to Underperform and lowered the price target from $10 to $8.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:36 am

WSFS

DA Davidson analyst Russell Gunther upgrades WSFS Financial (NASDAQ:WSFS) from Neutral to Buy and raises the price target from $38 to $45.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:34 am

MRCY

JP Morgan analyst Seth Seifman downgrades Mercury Sys (NASDAQ:MRCY) from Overweight to Neutral and lowers the price target from $56 to $37.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:33 am

BURL

Gordon Haskett analyst Chuck Grom upgrades Burlington Stores (NYSE:BURL) from Accumulate to Buy and lowers the price target from $200 to $175.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:30 am

ACCD

Needham analyst Ryan MacDonald has reiterated a Buy rating on Accolade (NASDAQ:ACCD) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:27 am

BMEA

HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Biomea Fusion (NASDAQ:BMEA) and raises the price target from $37 to $50.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:20 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:19 am

ASLN

HC Wainwright & Co. analyst Yi Chen reiterated a Buy rating on ASLAN Pharma (NASDAQ:ASLN) and maintained a $17 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:18 am